Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $24.74 million versus the consensus estimate of $8.02 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.